Due to a limited supply, we are unable to accept phone calls to schedule COVID-19 vaccinations.
For the most up-to-date information, please check our COVID-19 Vaccination Website.
PHILADELPHIA (October 30, 2020) – Pathogenic variants in DNA damage response and repair (DDRR) genes have been identified in patients with early onset renal cancer, according to a recent study by researchers at Fox Chase Cancer Center.
PHILADELPHIA (October 29, 2020)—Researchers from Fox Chase Cancer Center have presented new data indicating that several factors, the most significant one being pain, are significantly associated with a reduction in the number of working days per week in patients who attempt to work while receiving radiation treatment for head and neck cancer (HNC).
PHILADELPHIA (October 26, 2020)— Fox Chase Cancer Center is proud to support the Pancreatic Cancer Action Network (PanCAN) for PurpleStride Philadelphia 2020. Fox Chase will participate virtually with pancreatic cancer survivors, their loved ones, caregivers, and researchers on Saturday, November 7, 2020, to raise money for pancreatic cancer research and patient services.
PHILADELPHIA (October 26, 2020)—Researchers from Fox Chase Cancer Center have presented new data that shows that moderately hypofractionated photon and proton therapies are both safe for patients with low- or intermediate-risk prostate cancer.
PHILADELPHIA (October 23, 2020) – Researchers at Fox Chase Cancer Center have discovered a potential new target in the treatment of endometrial carcinoma, thanks in part to generous funding from Peggy’s Pathway for Women’s Cancer Care. The research was published recently in Molecular & Cellular Proteomics.
PHILADELPHIA (October 22, 2020)—Erica Golemis, PhD, deputy chief science officer and co-leader of the Molecular Therapeutics research program at Fox Chase Cancer Center, was recently appointed senior editor at eLife, an open-access, peer-reviewed journal.
PHILADELPHIA (October 13, 2020)—Fox Chase Cancer Center has unveiled a new micro-ultrasound system that physicians say could change the way prostate cancer is diagnosed.
